How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)
In recent years there have been major advances in the use of molecular diagnostic and
monitoring techniques for patients with acute myeloid leukaemia (AML). Coupled with the …
monitoring techniques for patients with acute myeloid leukaemia (AML). Coupled with the …
Assessment of minimal residual disease in standard-risk AML
A Ivey, RK Hills, MA Simpson… - … England Journal of …, 2016 - Mass Medical Soc
Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia
(AML), treatment decisions are based on a limited number of molecular genetic markers and …
(AML), treatment decisions are based on a limited number of molecular genetic markers and …
[HTML][HTML] Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical …
A Lesieur, X Thomas, O Nibourel, N Boissel… - …, 2021 - ncbi.nlm.nih.gov
In patients with acute myeloid leukemia (AML), treatment stratification is primarily based on
pre-therapeutic factors, including cytogenetic and molecular aberrations and …
pre-therapeutic factors, including cytogenetic and molecular aberrations and …
[HTML][HTML] P503: a randomised trial of molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI …
N Potter, J Jovanovic, A Ivey, A Thomas… - …, 2023 - journals.lww.com
Background: Several studies have demonstrated the prognostic impact of measurable
residual disease (MRD) evaluated by molecular methods in patients with AML with recurrent …
residual disease (MRD) evaluated by molecular methods in patients with AML with recurrent …
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
E Delsing Malmberg, S Johansson Alm… - Leukemia & …, 2019 - Taylor & Francis
Mutations in NPM1 can be used for minimal residual disease (MRD) analysis in acute
myeloid leukemia (AML). We here applied a newly introduced method, deep sequencing …
myeloid leukemia (AML). We here applied a newly introduced method, deep sequencing …
[HTML][HTML] Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
Acute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized as a
distinct entity, due to its unique biological and clinical features. We summarize here the …
distinct entity, due to its unique biological and clinical features. We summarize here the …
[HTML][HTML] Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations
The presence of minimal residual disease (MRD) is widely recognized as a powerful
predictor of therapeutic outcome in acute myeloid leukemia (AML), but methods of …
predictor of therapeutic outcome in acute myeloid leukemia (AML), but methods of …
[HTML][HTML] Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Detection of minimal residual disease predicts adverse outcome in patients with acute
myeloid leukemia. Currently, minimal residual disease may be detected by RQ-PCR or flow …
myeloid leukemia. Currently, minimal residual disease may be detected by RQ-PCR or flow …
[HTML][HTML] Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation
U Bacher, A Badbaran, B Fehse, T Zabelina… - Experimental …, 2009 - Elsevier
BACKGROUND: Minimal residual disease (MRD) diagnostics in acute myeloid leukemia
(AML) gain increasing importance after allogeneic stem cell transplantation (SCT) …
(AML) gain increasing importance after allogeneic stem cell transplantation (SCT) …
[HTML][HTML] Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high …
M Hubmann, T Köhnke, E Hoster, S Schneider… - …, 2014 - ncbi.nlm.nih.gov
Monitoring minimal residual disease is an important way to identify patients with acute
myeloid leukemia at high risk of relapse. In this study we investigated the prognostic …
myeloid leukemia at high risk of relapse. In this study we investigated the prognostic …